

SOFIE
From start to clinic

FAPI diagnostic- clinical development updates

FAP Ligands for Imaging and Therapy- SNMMI 2023


June 25th, 23

Sherly Mosessian Ph.D.

Chief Scientific Officer



Sherly.Mosessian@sofie.com

(Fibroblast Activation Protein Inhibitor)-**FAP**I family of compounds




Licensed by SOFIE from Heidelberg University for Diagnostic and Companion Diagnostic use

Publication analysis


	Total Publications/Patients with ALL FAP targeted radiopharmaceuticals	Publications/Patients with FAPI family of compounds
 # of patients reported	5903	5321 90% 4234- Oncology 1087- non-oncology
 # of publications	464	396 85%

Takeaway: FAPI family of compounds comprise the majority of publications and patient reported data to date (May 2023). *(Review articles are excluded)*

of patients/publications in various oncologic disease



GI cancers encompass the largest number of patients reported with FAPI



Phase 2 in patients with Pancreatic Ductal Adenocarcinoma (PDAC)



68 minutes half life



4 sites activated

- NYU Langone
- Mayo Clinic
- UCLA
- BAMF Health



60 patients planned

- 21 patients imaged

IND granted for FAP targeting therapeutic in SOFIE partnership


Lead Gallium-68 product

Can be utilized for theranostic use

Study launched May 2022

Companion diagnostic partnerships

Family of compounds



Phase 2 in patients with GI Cancers:
hepatocellular carcinoma, gastric cancer
cholangiocarcinoma, colorectal cancer
and pancreatic cancer



110 minutes half life



5 sites selected

- MGH activated
- 4 sites in activation process



120 patients planned

- 2 patient imaged

First Patient Imaged in SOFIE's 18F-FAPI Phase II trial



Lead Fluorine-18 product

Study launched May 2023

Automated synthesis and consumables
available with Trasis Mini-AIO and AIO

Companion diagnostic partnerships

SOFIE's FAPI Global Outreach Program



- 39 Countries
- 227 research studies
- 126 unique institutions

**Gain access to GMP
grade FAPI precursor**

**Manufacturing and
regulatory support**

**Expand grant and
research opportunities**



To improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of radiopharmaceuticals.



Our Pipeline

With over 50 years of passion and dedication for the future of PET, we have taken bold steps to advance the development of next generation radiopharmaceuticals.

[VIEW PIPELINE](#)



Partnership

We offer a range of contract manufacturing services to meet your clinical needs through our network and new Theranostics Center of Excellence.

[VIEW SERVICES](#)



PET Education

We have created a multifaceted approach designed to strengthen the quality of PET programs in your practice and deliver enhanced care to your patients.

[LEARN MORE](#)



Our Network

We have 14 network sites committed to on-time delivery of radiopharmaceuticals to meet our clients' need in diagnosing and treating critical illnesses every day.

[FIND A PHARMACY](#)

Thank you

For FAPI-related inquiries, e-mail us:
FAPIprogram@sofie.com

